Objective
Seeks long-term capital appreciation.
Overview
A stock fund that invests exclusively in health care, a sector that is experiencing innovations and breakthroughs across multiple subsectors.
The portfolio managers are supported by the full resources of Wellington.
Performance
Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted.
SI = Since Inception.
Fund Inception: 05/01/2000
Share Class Inception: 2/28/17.
Class F-shares performance prior to 2/28/17 reflects Class I-shares performance and operating expenses, and, prior to 8/31/06 the performance and operating expenses of Class A-shares (excluding sales charges). Performance for Class F-shares prior to its inception date would have differed if Class F- operating expenses had been reflected. Since Inception (SI) performance is calculated from 5/1/00.
Characteristics
# of Holdings | 102 |
---|---|
% in Equities | 99 |
% in Foreign Equities | 16 |
Beta (3 year) | 0.99 |
R Squared (3 year) | 0.91 |
Standard Deviation | 15.32% |
Turnover | 32% |
Active Share | 47% |
FUND | S&P Composite 1500 Health Care Index | |
---|---|---|
Price/Earnings | 28.9x | 18.4x |
Price/Book | 5.7x | 5.3x |
EPS Growth Rate | 22.3% | 17.1% |
Asset Weighted Market Cap (billions) | $230.8 | $284.9 |
Return on Equity | 20.3% | 33.6% |
Median Market Cap (billions) | $10.5 | $7.2 |
Eli Lilly & Co. | 11.39 |
UnitedHealth Group, Inc. | 8.69 |
Merck & Co., Inc. | 3.58 |
Danaher Corp. | 3.53 |
Boston Scientific Corp. | 3.25 |
Thermo Fisher Scientific, Inc. | 2.90 |
Vertex Pharmaceuticals, Inc. | 2.51 |
Stryker Corp. | 2.36 |
HCA Healthcare, Inc. | 2.17 |
AstraZeneca PLC | 2.04 |
Total Portfolio % | 42.42 |
Less than $2 billion | 3 | |
$2 billion - $5 billion | 8 | |
$5 billion - $10 billion | 9 | |
Greater than $10 billion | 80 | |
Not Classified | 0 |
Alpha (5 Year)
|
-1.53 |
Down Capture (5 Year)
|
102.46 |
Information Ratio (5 Year)
|
-0.35 |
Sharpe Ratio (5 Year)
|
0.58 |
Up Capture (5 Year)
|
95.84 |
Insights
Fund Literature